Complement activation products in liquid stored plasma and C3a kinetics after transfusion of autologous plasma

Norda, Rut; Schött, Ulf; Berséus, Olle; Åkerblom, Olof; Nilsson, Bo; Ekdahl, Kristina Nilsson; Stegmayr, Bernd; Knutson, Folke

doi:10.1111/j.1423-0410.2011.01522.x

Cited by 30 publications

(16 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Activation of C3 may be monitored either by identifying the protein fragment C3a, which is generated in the first proteolytic cleavage step, or the C3d,g fragment, which is the end product (together with C3c) (Figure 2). These peptides vary greatly with regard to their half-lives ( T 1/2 ) in vivo : approximately 0.5 hr for C3a [29] and 4 hr for C3d,g [30]. In addition, there is a great risk that C3a will be generated in vitro during improper handling of samples.…”

Section: Methodsmentioning

confidence: 99%

Complement Diagnostics: Concepts, Indications, and Practical Guidelines

Nilsson

Ekdahl

2012

Clinical and Developmental Immunology

View full text Add to dashboard Cite

Aberrations in the complement system have been shown to be direct or indirect pathophysiological mechanisms in a number of diseases and pathological conditions such as autoimmune disease, infections, cancer, allogeneic and xenogeneic transplantation, and inflammation. Complement analyses have been performed on these conditions in both prospective and retrospective studies and significant differences have been found between groups of patients, but in many diseases, it has not been possible to make predictions for individual patients because of the lack of sensitivity and specificity of many of the assays used. The basic indications for serological diagnostic complement analysis today may be divided into three major categories: (a) acquired and inherited complement deficiencies; (b) disorders with complement activation; (c) inherited and acquired C1INH deficiencies. Here, we summarize indications, techniques, and interpretations for basic complement analyses and present an algorithm, which we follow in our routine laboratory.

show abstract

Section: Methodsmentioning

confidence: 99%

Complement Diagnostics: Concepts, Indications, and Practical Guidelines

Nilsson

Ekdahl

2012

Clinical and Developmental Immunology

View full text Add to dashboard Cite

show abstract

“…Rather, the explanation appears to involve the physiological, alternative pathway-mediated turnover (tick-over) of C3, which generates C3b and C3a-desArg at a slow rate and is dependent on the total plasma concentration of C3. The effect of the turnover of C3 is a constant generation of the fragment C3a-desArg, which circulates in plasma at a concentration of 80-120 ng/L in healthy individuals (Norda et al, 2012). In obese persons, these levels are increased due to the elevated C3 concentration.…”

Section: Alternative Pathway Activation and Generation Of C3a And C5amentioning

confidence: 99%

The role of complement factor C3 in lipid metabolism

Barbu

Hamad

Lind

et al. 2015

Molecular Immunology

View full text Add to dashboard Cite

“…The latter authors have suggested therefore that liquid plasma should be produced from males to reduce this effect, and to limit the storage time to 7 days. Markers of complement activation C3a desarg and sC5b‐9 also increase during storage of liquid plasma, the magnitude of which depends on how the plasma has been produced . However, once generated C3a and C5a, both anaphylatoxins, are rapidly converted in plasma to forms that are less active and are eliminated following transfusion.…”

Section: Liquid ‘Never Frozen’ Plasmamentioning

confidence: 99%

Thawed and liquid plasma – what do we know?

Cardigan

Green

2015

Vox Sanguinis

View full text Add to dashboard Cite

There is increasing interest in the use of liquid or frozen plasma thawed and stored for extended periods (>24 h) to reduce wastage and to improve rapid availability of plasma in massive transfusion protocols advocating the early use of plasma in trauma by some centres. There is now a body of studies that have assessed individual coagulation factors during storage of thawed plasma. These show that factor VIII (FVIII) is the worst affected factor and that its activity is mainly lost during the first 24 h following thawing. However, for most factors studied, there is a continual decline during further storage. The few studies that have assessed thrombin generation in thawed plasma have shown variable results. Extended storage of plasma is associated with an increase in levels of DEHP in the component and could theoretically increase the risk of bacterial contamination, although the latter does not appear to have been an issue in countries that have adopted the use of thawed plasma. There are no clinical studies relating to the efficacy of extended-thawed plasma, and therefore, the potential reduction in its efficacy must be balanced with the clinical need for the component.

show abstract

Complement activation products in liquid stored plasma and C3a kinetics after transfusion of autologous plasma

Cited by 30 publications

References 45 publications

Complement Diagnostics: Concepts, Indications, and Practical Guidelines

Complement Diagnostics: Concepts, Indications, and Practical Guidelines

The role of complement factor C3 in lipid metabolism

Thawed and liquid plasma – what do we know?

Contact Info

Product

Resources

About